Literature DB >> 33747931

Establishment of a Macrophage Phenotypic Switch Related Prognostic Signature in Patients With Pancreatic Cancer.

Mu-Xing Li1, Hang-Yan Wang1, Chun-Hui Yuan1, Zhao-Lai Ma1, Bin Jiang1, Lei Li1, Li Zhang1, Dian-Rong Xiu1.   

Abstract

INTRODUCTION: Macrophage phenotype switch plays a vital role in the progression of malignancies. We aimed to build a prognostic signature by exploring the expression pattern of macrophage phenotypic switch related genes (MRGs) in the Cancer Genome Atlas (TCGA)-pancreatic adenocarcinoma (PAAD), Genotype-Tissue Expression (GTEx)-Pancreas, and Gene Expression Omnibus (GEO) databases.
METHODS: We identified the differentially expressed genes between the PAAD and normal tissues. We used single factor Cox proportional risk regression analysis, Least Absolute Shrinkage and Selection Operator (LASSO) analysis, and multivariate Cox proportional hazard regression analysis to establish the prognosis risk score by the MRGs. The relationships between the risk score and immune landscape, "key driver" mutations and clinicopathological factors were also analyzed. Gene-set enrichment analysis (GSEA) analysis was also performed.
RESULTS: We detected 198 differentially expressed MRGs. The risk score was constructed based on 9 genes (KIF23, BIN1, LAPTM4A, ERAP2, ATP8B2, FAM118A, RGS16, ELMO1, RAPGEFL1). The median overall survival time of patients in the low-risk group was significantly longer than that of patients in the high-risk group (P < 0.001). The prognostic value of the risk score was validated in GSE62452 dataset. The prognostic performance of nomogram based on risk score was superior to that of TNM stage. And GSEA analysis also showed that the risk score was closely related with P53 signaling pathway, pancreatic cancer and T cell receptor signaling pathway. qRT-PCR assay showed that the expressions of the 9 MRGs in PDAC cell lines were higher than those in human pancreatic ductal epithelium cell line.
CONCLUSIONS: The nine gene risk score could be used as an independent prognostic index for PAAD patients. Further studies validating the prognostic value of the risk score are warranted.
Copyright © 2021 Li, Wang, Yuan, Ma, Jiang, Li, Zhang and Xiu.

Entities:  

Keywords:  GEO; GTEx; TCGA; macrophage phenotype switch; pancreatic ductal adenocarcinoma; prognostic index

Year:  2021        PMID: 33747931      PMCID: PMC7966706          DOI: 10.3389/fonc.2021.619517

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  35 in total

1.  Selection of important variables and determination of functional form for continuous predictors in multivariable model building.

Authors:  Willi Sauerbrei; Patrick Royston; Harald Binder
Journal:  Stat Med       Date:  2007-12-30       Impact factor: 2.373

2.  Genomic analyses identify molecular subtypes of pancreatic cancer.

Authors:  Peter Bailey; David K Chang; Katia Nones; Amber L Johns; Ann-Marie Patch; Marie-Claude Gingras; David K Miller; Angelika N Christ; Tim J C Bruxner; Michael C Quinn; Craig Nourse; L Charles Murtaugh; Ivon Harliwong; Senel Idrisoglu; Suzanne Manning; Ehsan Nourbakhsh; Shivangi Wani; Lynn Fink; Oliver Holmes; Venessa Chin; Matthew J Anderson; Stephen Kazakoff; Conrad Leonard; Felicity Newell; Nick Waddell; Scott Wood; Qinying Xu; Peter J Wilson; Nicole Cloonan; Karin S Kassahn; Darrin Taylor; Kelly Quek; Alan Robertson; Lorena Pantano; Laura Mincarelli; Luis N Sanchez; Lisa Evers; Jianmin Wu; Mark Pinese; Mark J Cowley; Marc D Jones; Emily K Colvin; Adnan M Nagrial; Emily S Humphrey; Lorraine A Chantrill; Amanda Mawson; Jeremy Humphris; Angela Chou; Marina Pajic; Christopher J Scarlett; Andreia V Pinho; Marc Giry-Laterriere; Ilse Rooman; Jaswinder S Samra; James G Kench; Jessica A Lovell; Neil D Merrett; Christopher W Toon; Krishna Epari; Nam Q Nguyen; Andrew Barbour; Nikolajs Zeps; Kim Moran-Jones; Nigel B Jamieson; Janet S Graham; Fraser Duthie; Karin Oien; Jane Hair; Robert Grützmann; Anirban Maitra; Christine A Iacobuzio-Donahue; Christopher L Wolfgang; Richard A Morgan; Rita T Lawlor; Vincenzo Corbo; Claudio Bassi; Borislav Rusev; Paola Capelli; Roberto Salvia; Giampaolo Tortora; Debabrata Mukhopadhyay; Gloria M Petersen; Donna M Munzy; William E Fisher; Saadia A Karim; James R Eshleman; Ralph H Hruban; Christian Pilarsky; Jennifer P Morton; Owen J Sansom; Aldo Scarpa; Elizabeth A Musgrove; Ulla-Maja Hagbo Bailey; Oliver Hofmann; Robert L Sutherland; David A Wheeler; Anthony J Gill; Richard A Gibbs; John V Pearson; Nicola Waddell; Andrew V Biankin; Sean M Grimmond
Journal:  Nature       Date:  2016-02-24       Impact factor: 49.962

3.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

4.  Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter?

Authors:  Irit Ben-Aharon; Moshe Elkabets; Raphael Pelossof; Kenneth H Yu; Christine A Iacubuzio-Donahue; Steven D Leach; Maeve A Lowery; Karyn A Goodman; Eileen M O'Reilly
Journal:  Clin Cancer Res       Date:  2019-01-07       Impact factor: 12.531

5.  Loss of natural killer T cells promotes pancreatic cancer in LSL-KrasG12D/+ mice.

Authors:  Naveena B Janakiram; Altaf Mohammed; Taylor Bryant; Rebekah Ritchie; Nicole Stratton; Lydgia Jackson; Stan Lightfoot; Doris M Benbrook; Adam S Asch; Mark L Lang; Chinthalapally V Rao
Journal:  Immunology       Date:  2017-05-29       Impact factor: 7.397

Review 6.  Challenges and Opportunities for Pancreatic Cancer Immunotherapy.

Authors:  Adham S Bear; Robert H Vonderheide; Mark H O'Hara
Journal:  Cancer Cell       Date:  2020-09-17       Impact factor: 31.743

7.  PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis.

Authors:  Masayo Tsukamoto; Katsunori Imai; Takatsugu Ishimoto; Yoshihiro Komohara; Yo-Ichi Yamashita; Shigeki Nakagawa; Naoki Umezaki; Takanobu Yamao; Yuki Kitano; Tatsunori Miyata; Kota Arima; Hirohisa Okabe; Yoshifumi Baba; Akira Chikamoto; Takatoshi Ishiko; Masahiko Hirota; Hideo Baba
Journal:  Cancer Sci       Date:  2018-12-14       Impact factor: 6.716

8.  Murine xenograft bioreactors for human immunopeptidome discovery.

Authors:  James M Heather; Paisley T Myers; Feng Shi; Mohammad Ovais Aziz-Zanjani; Keira E Mahoney; Matthew Perez; Benjamin Morin; Christine Brittsan; Jeffrey Shabanowitz; Donald F Hunt; Mark Cobbold
Journal:  Sci Rep       Date:  2019-12-06       Impact factor: 4.379

Review 9.  T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer?

Authors:  Qi Zhou; Xufeng Tao; Shilin Xia; Fangyue Guo; Chen Pan; Hong Xiang; Dong Shang
Journal:  Front Oncol       Date:  2020-03-24       Impact factor: 6.244

View more
  5 in total

Review 1.  Role of ELMO1 in inflammation and cancer-clinical implications.

Authors:  Stefania Tocci; Stella-Rita Ibeawuchi; Soumita Das; Ibrahim M Sayed
Journal:  Cell Oncol (Dordr)       Date:  2022-06-06       Impact factor: 7.051

2.  Systematic Analysis of an Invasion-Related 3-Gene Signature and Its Validation as a Prognostic Model for Pancreatic Cancer.

Authors:  Dafeng Xu; Yu Wang; Yuliang Zhang; Zhehao Liu; Yonghai Chen; Jinfang Zheng
Journal:  Front Oncol       Date:  2021-12-15       Impact factor: 6.244

3.  Establishing a Macrophage Phenotypic Switch-Associated Signature-Based Risk Model for Predicting the Prognoses of Lung Adenocarcinoma.

Authors:  Jun Chen; Chao Zhou; Ying Liu
Journal:  Front Oncol       Date:  2022-02-23       Impact factor: 6.244

4.  Novel estrogen-responsive genes (ERGs) for the evaluation of estrogenic activity.

Authors:  Kentaro Nishi; Wenqiang Fu; Ryoiti Kiyama
Journal:  PLoS One       Date:  2022-08-17       Impact factor: 3.752

5.  Exploring the Potential of Pyroptosis-Related Genes in Predicting Prognosis and Immunological Characteristics of Pancreatic Cancer From the Perspective of Genome and Transcriptome.

Authors:  Jing Zhang; Xiaomin You; Dong Kang; Guoxiong Zhou
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.